Drug Design, Development and Therapy (Mar 2024)
A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
Abstract
Mingyue Wang,1– 4 Xing-Hua Gao,1– 4 Li Zhang1 1Department of Dermatology, the First Hospital of China Medical University, Shenyang, 110001, People’s Republic of China; 2NHC Key Laboratory of Immunodermatology, China Medical University, Shenyang, People’s Republic of China; 3Key Laboratory of Immunodermatology, China Medical University, Ministry of Education, Shenyang, People’s Republic of China; 4National and Local Joint Engineering Research Center of Immunodermatological Theranostics, Shenyang, People’s Republic of ChinaCorrespondence: Li Zhang, Department of Dermatology, the First Hospital of China Medical University, Shenyang, 110001, People’s Republic of China, Email [email protected]: Atopic dermatitis (AD), a common pruritic and chronic inflammatory skin disease, has a major impact on a patient’s quality of life. It is characterized by dry, itchy, and eczema-like rashes. AD is more prevalent in young children and has been linked to a variety of other allergy disorders. Traditional drug therapy has certain limitations for treating young children with AD. However, biologics have good clinical application prospects in the medical treatment of young patients. Dupilumab, a fully human monoclonal antibody, specifically binds to the IL-4 Rα subunit, inhibiting IL-4 and IL-13 signaling and blocking the occurrence of type 2 inflammatory response. It has a good effect on treating infants and children with moderate-to-severe AD. This review explores the safety and efficacy of dupilumab in the treatment of AD in infants and children and the impact of early intervention on AD progression, with the aim of informing clinical practice in the use of dupilumab for the treatment of young patients with AD.Keywords: atopic dermatitis, dupilumab, infant, child, treatment
